The world's first portable electrocardiograph was an 85-pound backpack, and now a 10-gram patch attached to your chest can transmit electrocardiograms uninterrupted for two weeks. The Apple Watch, which is worn by an estimated 100 million people, can send a text message to alert people when their heartbeat is irregular. Wearable sensors on the arms, wrists and fingers can now report arrhythmias, blood sugar levels, blood oxygen and other health indicators. Medical journals have also proposed a more ambitious vision - wearable devices can monitor patients with chronic diseases, eliminating the need for frequent hospital visits. They can spot potential health problems before a stroke or diabetes develops. The forces of health technology and wearables are converging. Tech giants like Apple (AAPL) and Alphabet's (GOOGL) Google are adding health features to their products. Medical technologists like electrocardiogram patch maker iRhythm Technologies or blood sugar monitor makers DexCom (DXCM) and Abbott Laboratories (ABT) are taking their devices beyond the clinic. "In the sensor world, people started on the consumer side and wanted to get into health care," said Kevin Sayer, chief executive of Decon Medical. "In health care, we're trying to be more consumer oriented, and I think all of those things are sort of colliding." Early bets favored the tech giants, with every health-related announcement from Apple, Google or Samsung Electronics hitting medical tech stocks. But changing doctors' practices will also require sustained investment in clinical trials. Big tech companies have cut back on investments in health care. Now it seems that medical technologists will be at the vanguard of the digital health revolution - with smartwatches and smart rings bringing them more customers who need to be diagnosed. Blake Goodner, co-founder of Bridger Management, a hedge fund focused on health care, said: "A group of medtech companies focused on digital health are maturing and reaching a scale where they can not only be profitable but also make investments to compete with larger tech companies." Tech giants aren't getting out of the health business. Apple's smartwatch has an electronic heart rate sensor that generates a single-point electrocardiogram, a wrist temperature sensor, and an accelerometer that can detect violent falls. Hundreds of millions of people are wearing smartwatches with health features from Apple or its rivals Samsung and Garmin.

The returner of the Chang'e-6 lunar probe is opened during a ceremony at the China Academy of Space Technology under the China Aerospace Science and Technology Corporation in Beijing, capital of China, June 26, 2024. The returner of the Chang'e-6 lunar probe was opened at a ceremony in Beijing on Wednesday afternoon. During the ceremony at the China Academy of Space Technology under the China Aerospace Science and Technology Corporation, researchers opened the returner and examined key technical indicators. Photo: Xinhua As the US space industry recently faced yet more delays and stagnation with key components including manned spacecraft and space suits "going wrong," NASA has once again resorted to its "sour grapes" rhetoric upon seeing China's successful retrieval of fresh lunar soils from the far side of the moon, by claiming that China did not directly invite its scientists to participate in the lunar soil research. This behavior is a typical blame-shifting trick, Chinese experts said, noting it is clear to all that it is the US' own laws, not China, that are restricting space cooperation between the two sides. Instead of deceiving themselves by distorting the truth, the US should face up to its own problem of overall weakening engineering capability and the lack of long-term planning in its space industry. After the Chang'e-6 samples, weighing nearly 2 kilograms, were safely transported to a special laboratory for further study on Friday, NASA spokesperson Faith McKie told media that while China worked with the European Space Agency, France, Italy and Pakistan on this mission, "NASA wasn't invited to take part in the moon probe." NASA also didn't get "any direct invitation" to study China's moon rocks, after it welcomed all scientists from around the world to apply to study them, McKie told NatSec Daily. Responding to the remarks, Chinese Foreign Ministry spokesperson Mao Ning told the Global Times on Monday that China is open to having space exchanges with the US, and we also welcome countries around the world to take part in the study of lunar samples. "However, the US side seems to have forgotten to mention its domestic legislation such as the Wolf Amendment. The real question is whether US scientists and institutions are allowed by their own government to participate in cooperation with China," Mao said. "The existence of the Wolf Amendment has basically shut the door to space collaboration between the two countries," Wang Yanan, chief editor of Beijing-based Aerospace Knowledge magazine, told the Global Times on Monday. Even if research institutions of the US have the willingness to work with China on opportunities such as lunar sample research, institutions there must obtain special approval from the US Congress due to the presence of this amendment, Wang explained. Currently, no such "green light" is in sight from the Congress. Furthermore, China's collaboration with international partners is based on equality and mutual benefit, leveraging their respective scientific resources, facilities, and expertise. However, the US only wants what it doesn't have, and its engagement with China would be advantageous only to itself, Wang noted. NASA has found itself embroiled in a number of thorny issues recently, with the latest being Boeing's Starliner manned spaceship experiencing both helium leaks and thruster issues during a June 6 docking with the International Space Station (ISS), which led to an indefinite delay for its crew's return to Earth, despite NASA's insistence that they are not "stranded" in space. The return of the Starliner capsule, while has already been delayed by two weeks, will be put on hold "well into the summer" pending results of new thruster tests, which are scheduled to start Tuesday and will take approximately two weeks or even more, per NASA officials. Previously on June 24, NASA cancelled a spacewalk on the ISS following a "serious situation," when one of the spacesuits experienced coolant leak in the hatch. While being broadcast on a livestream, the astronauts reported "literally water everywhere" as they were preparing for the extravehicular activity, space.com reported. The report said that this is the second time this particular spacewalk was postponed, after a June 13 attempt with a different astronaut group was pushed back due to a "spacesuit discomfort." The recurring issues with the spacesuits are due to their much-extended service lifespan, media reported, as the puffy white ones US astronauts currently wear were designed more than 40 years ago. Despite the pressing need to replace them, NASA announced recently that it is abandoning a plan to develop next-generation spacesuits, which had been committed to be delivered by 2026, CNN reported on Thursday. One of the root causes for such problems is that the US has developed many large technology conglomerates, which for a long time have benefited significantly from government orders and industry monopolies. Consequently, in many complex engineering fields, the level of attention given is greatly insufficient, Wang noted. It also reflected the US' lack of long-term strategic planning for its manned space program. For instance, the ageing spacesuits should have been replaced a decade ago to ensure that operational suits remain in usable condition. Failure to address this issue results in a hindrance to the space station's necessary maintenance tasks and even poses life-threatening risks to astronauts in emergency situations, experts said. The issues with Boeing's spacecraft and the spacesuits are not isolated problems, but reflected a systemic issue in the US space industry - the overall weakening of engineering capabilities, they noted.

Carlsberg to buy Britvic for 1,315p per share Carlsberg will also buy out Marston's from brewing joint venture Danish brewer plans to create integrated beverage business in UK Shares in Carlsberg, Britvic, Marston's all rise July 8 (Reuters) - Carlsberg (CARLb.CO), opens new tab has agreed to buy British soft drinks maker Britvic (BVIC.L), opens new tab for 3.3 billion pounds ($4.23 billion), a move the Danish brewer said would forge a UK beverage "powerhouse" and that sent both companies' shares higher. Carlsberg clinched the takeover with a sweetened bid of 1,315 pence per share - comprising cash and a special dividend of 25 pence a share - after the British company rejected 1,250 pence per share last month. The acquisition will create value for shareholders, contribute to growth and forge a combined beer and soft drink company that is unique in the UK, CEO Jacob Aarup-Andersen told investors on a conference call. "With this transaction we are creating a UK powerhouse," he said. He brushed off concerns from some analysts about integration risks, saying Carlsberg has a strong track record of running beer and soft drink businesses in several markets. Soft drinks already make up 16% of Carlsberg's volumes. COST SAVINGS As drinkers in some markets ditch beer for spirits or cut back on drinking altogether, brewers have looked to broaden their portfolio into new categories like hard seltzer, canned cocktails and cider, as well as zero-alcohol brews. Britvic sells non-alcoholic drinks in Britain, Ireland, Brazil and other international markets such as France, the Middle East and Asia. Carlsberg said the deal will deliver a number of benefits, including cost and efficiency savings worth 100 million pounds ($128 million) over five years as it takes advantage of common procurement, production and distribution networks. It will also see Carlsberg take over Britvic's bottling agreement with PepsiCo (PEP.O), opens new tab. Carlsberg already bottles PepsiCo drinks in several markets and there is scope to add more geographies in future, Aarup-Andersen said. arlsberg halted share buy backs on Monday as a result of the deal. Chief financial officer Ulrica Fearn said these would resume once Carlsberg reaches its revised target for net debt of 2.5 times EBITDA, from 3.5 times currently - a goal it expects to meet in 2027. "Whilst this represents a shift in the strategy away from organic top- and bottom-line growth and consistent returns to shareholders, we view it as a relatively low risk transaction with attractive financials," Jefferies analysts said in a note. Carlsberg also said on Monday it will buy out UK pub group Marston's (MARS.L), opens new tab from a joint venture for 206 million pounds. That will give it full ownership of the newly formed Carlsberg Britvic after the deal. ($1 = 0.7805 pounds) Get the latest news and expert analysis about the state of the global economy with Reuters Econ World. Sign up here. Reporting by Stine Jacobsen, Yadarisa Shabong and Emma Rumney Editing by Sherry Jacob-Phillips, Rashmi Aich, David Goodman and David Evans

On the evening of July 8, local time, the Israel Defense Forces issued a statement saying that Major General Avi Bluth replaced Yehuda Fox as the commander of the Israeli Central Command. Earlier that day, the Israeli army held a handover ceremony, which was presided over by the Israeli Chief of Staff Halevy. Avi Bluth joined the Israel Defense Forces in 1993 and commanded the Israeli military operations in the West Bank. In May this year, Bruce was promoted to major general and served as a military commander in the Israeli Central Command. CCTV reporters learned that in late April this year, Yehuda Fox, then commander of the Israeli Central Command, requested to resign and retire from the army in August this year. Fox had previously stated that he should bear part of the responsibility for the military intelligence failure on October 7 last year, and "must end his term like everyone else." According to the official website of the Israeli Defense Forces, the Central Command is one of the four major commands of the Israeli army, headquartered in Jerusalem, and its responsibility covers nearly one-third of Israel's territory.

White House spokeswoman Karina Jean-Pierre denied a report in the U.S. media on the 8th that President Joseph Biden did not receive treatment for Parkinson's disease. Biden had the first televised debate of the 2024 presidential election with Republican opponent Donald Trump on June 27, and his poor performance on the spot triggered discussions about his physical condition. The New York Times reported that a doctor specializing in the treatment of Parkinson's disease had "visited" the White House eight times from August last year to March this year. Facing the media's questions about Biden's health, Jean-Pierre asked and answered himself at a regular White House press conference on the 8th: "Has the president received treatment for Parkinson's disease? No. Is he currently receiving treatment for Parkinson's disease? No, he is not. Is he taking medication for Parkinson's disease? No." Jean-Pierre said Biden had seen a neurologist three times, all related to his annual physical examination. She also took out the report issued by the doctor after Biden's most recent physical examination in February this year. The report said, "An extremely detailed neurological examination was once again reassuring" because no symptoms consistent with stroke, multiple sclerosis or Parkinson's disease were found. The doctor who went to the White House mentioned by the New York Times is Kevin Kanal, a neurology and movement disorder expert at the Walter Reed National Military Medical Center in Maryland and an authority on Parkinson's disease. Jean-Pierre suggested that the doctor might have come to treat military personnel on duty at the White House.